Accessibility Menu
3SBio logo

3SBio(OTC) TRSBF

Market Cap$5.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-11%
5 Year+197%
1 Year-46%
1 Month+0%
$2.12
+0.00%
+0.00Today
3SBio last closing stock price
MetricPriceDate
Last closeUSD 2.122026-08-18
3SBio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 2.122026-08-05
1 month+0%USD 2.122026-06-26
3 month-15.69%USD 2.512026-05-19
Year to date-39.61%USD 3.512025-12-26
1 year-46.25%USD 3.942025-08-18
3 year+187.47%USD 0.742023-04-18
5 year+196.92%USD 0.712021-08-09
Since inception-11.16%USD 2.422018-06-26

3SBio Financials at a Glance

Market Cap

$5.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥26.66B

Net Income (TTM)

CN¥10.50B

EPS (TTM)

$0.47

P/E Ratio

4.49

Dividend

$0.00

Beta (Volatility)

-0.08 (Low)

Price

$2.12

Volume

36,542

Open

$2.12

Previous Close

$2.12

Daily Range

$2.12 - $2.12

52-Week Range

$2.00 - $4.42

Estimated Earnings Date

Mar 30, 2027

TRSBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 3SBio

3SBio Inc. is a China-based biopharmaceutical company engaged in the entire value chain from research and development to manufacturing, marketing, and sales of innovative products. The company offers a diverse portfolio of treatments for various therapeutic needs, including blood disorders, autoimmune diseases, and oncology.

Products and Services
  • TPIAO for chemotherapy-induced thrombocytopenia
  • YISAIPU, a tumor necrosis factor inhibitor for autoimmune diseases
  • Cipterbin for HER2-positive metastatic breast cancer
Growth Outlook
  • Revenue of CNY 4.46 billion in Q2 2026, showing strong demand
  • Net income of CNY 1.13 billion in Q2 2026, indicating profitability
  • Strategic collaborations with global partners enhance market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 13.12 billion
  • Net profit margin of 46.37% reflects operational efficiency
  • Current ratio of 6.06 indicates strong liquidity position
3SBio Inc. has established itself as a key player in the biopharmaceutical sector, leveraging its extensive product offerings to address critical health needs. The company's recent financial performance demonstrates robust growth, with significant revenue and net income figures that highlight its operational success. The strong liquidity position, as indicated by the current ratio, provides a solid foundation for future investments and expansions. Additionally, strategic partnerships with renowned global firms position 3SBio for continued growth and innovation in the competitive biopharmaceutical landscape.
AI Generated • Aug 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6,109

CEO

Jing Lou, PhD, EMBA

Website

www.3sbio.com

Headquarters

Shenyang, LI 110027, CN

TRSBF Financials

Key Financial Metrics (TTM)

Gross Margin

91.97%

Operating Margin

61.16%

Net Income Margin

46.37%

Return on Equity

30.16%

Return on Capital

34.47%

Return on Assets

23.21%

Earnings Yield

22.27%

Dividend Yield

0.00%

Payout Ratio

6.54%

Stock Overview

Market Cap

$5.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.50B

Volume

36.54K

Avg. Volume

1.82K

Financials (TTM)

Gross Profit

CN¥23.91B

Operating Income

CN¥13.23B

EBITDA

CN¥14.38B

Operating Cash Flow

CN¥10.98B

Capital Expenditure

-CN¥1.05B

Free Cash Flow

CN¥9.92B

Cash & ST Invst.

CN¥17.60B

Total Debt

CN¥1.39B

3SBio Performance Analysis

3SBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 1,019,605,9783.0%
20232023-12-31CNY 1,103,162,5198.2%
20242024-12-31CNY 1,265,556,32614.7%
20252025-12-31CNY 2,461,692,54494.5%
3SBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-317.5%
Q22025-06-30-7.7%
Q42025-12-31201.2%
Q22026-06-30-66.0%
3SBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.1115.2%
20232023-12-31CNY 0.09-20.2%
20242024-12-31CNY 0.1233.7%
20252025-12-31CNY 0.48305.2%
3SBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-11.1%
Q22025-06-3040.0%
Q42025-12-31412.5%
Q22026-06-30-84.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥4.46B

+1.7%

Gross Profit

CN¥3.74B

-1.4%

Gross Margin

83.84%

N/A

Market Cap

$5.38BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$880.16K

N/A

Employees

6,109

N/A

Net Income

CN¥1.13B

+3.8%

EBITDA

CN¥1.88B

+12.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥17.60B

+204.7%

Total Debt

CN¥1.39B

-67.1%

Accounts Receivable

CN¥1.15B

-7.6%

Inventory

CN¥1.04B

+26.6%

Long Term Debt

CN¥767.43M

-28.6%

Short Term Debt

CN¥619.70M

-80.3%

Return on Assets

23.21%

N/A

Return on Invested Capital

33.86%

N/A

Free Cash Flow

CN¥0.00

-100.0%

Operating Cash Flow

CN¥0.00

-100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SHTDYSinopharm Group Co. Ltd.
$9.83+1.02%
REGMFRemeGen Co., Ltd.
$10.93+0.00%
SKHCFSonic Healthcare Limited
$13.65+0.00%
SSMXYSysmex Corporation
$12.46+3.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About TRSBF

What is the current price of 3SBio?

3SBio is trading at $2.12 per share.

What is the 52-week range for 3SBio?

Over the past 52 weeks, 3SBio has traded between $2.00 and $4.42.

How much debt does 3SBio have?

As of the most recent reporting period, 3SBio reported total debt of CN¥374.61M.

How much cash does 3SBio have on hand?

3SBio reported CN¥1.76B in cash and cash equivalents in its most recent financial results.

What is 3SBio’s dividend yield?

3SBio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services